Do you have a link to the specific LFT issues you're referring to? I'm not doubting you at all; I'd just like to see the magnitude of what you're referring to.
I like to think about things in terms of worst-case scenario. Not entirely worst-case scenario obviously (worst-case would be no role for roxa in any pop), but if roxa only has a role in just the EPO-resistant indications, I think that would be meaningful enough for the company (and support valuation).
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.